Search
                    Epilepsy Paid Clinical Trials in Texas
A listing of 28  Epilepsy  clinical trials  in Texas  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 28
        
                The state of Texas currently has 28 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin. 
            
                                Featured Trial
                
                Paid Clinical Studies Nationwide
            
        Recruiting
            
        Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
    
    
Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/20/2025
            
            Locations: ANESC Research, El Paso, Texas  +2 locations         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/19/2025
            
            Locations: Clinical Research Solution LLC, Cypress, Texas  +3 locations         
        
        
            Conditions: Generalized Epilepsy
        
            
        
    
                
                                    A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
                                
            
            
        Recruiting
                            
            
                This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/01/2025
            
            Locations: UTHealth Houston, Houston, Texas         
        
        
            Conditions: Epilepsy, Temporal Lobe
        
            
        
    
                
                                    SLC13A5 Deficiency Natural History Study - United States Only
                                
            
            
        Recruiting
                            
            
                SLC13A5 deficiency (Citrate Transporter Disorder, EIEE 25) is a rare genetic disorder with neurodevelopmental delays and seizure onset in the first few days of life. This natural history study is designed to address the lack of understanding of disease progression. Additionally it will identify clinical and biomarker endpoints for use in future clinical trials.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/28/2025
            
            Locations: University of Texas Southwestern Dallas, Dallas, Texas         
        
        
            Conditions: Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (Non-ROGDI), Citrate Transporter Disorder, DEE25
        
            
        
    
                
                                    AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
                                
            
            
        Recruiting
                            
            
                The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/24/2025
            
            Locations: Baylor Scott & White Medical Center, Austin, Texas         
        
        
            Conditions: Mesial Temporal Lobe Epilepsy
        
            
        
    
                
                                    Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
                                
            
            
        Recruiting
                            
            
                Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 18 years
            Trial Updated:
                07/23/2025
            
            Locations: Child Neurology Consultants of Austin, Austin, Texas  +1 locations         
        
        
            Conditions: Partial Epilepsy
        
            
        
    
                
                                    Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
                                
            
            
        Recruiting
                            
            
                Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is human's ability to respond correctly to novel contextual situations on the first attempt, without prior rehearsal. The investigators refer to this ability as 'ad hoc self-programming': 'ad hoc' because these new behavioral repertoires are cobbled together on the fly, based on immediate demand, and then discarded when no longer necessary; 'self-programming' becau...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 10 years and 64 years
            Trial Updated:
                07/17/2025
            
            Locations: Baylor College of Medicine, Houston, Texas         
        
        
            Conditions: Epilepsy
        
            
        
    
                
                                    Breathing Rescue for SUDEP Prevention
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/13/2025
            
            Locations: The University of Texas Health Science Center at Houston, Houston, Texas         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.
                                
            
            
        Recruiting
                            
            
                The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording.
The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region .
2-5 sites in Europe Up to 10 sites in U...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                05/09/2025
            
            Locations: UT Health Houston, Houston, Texas         
        
        
            Conditions: Epilepsy
        
            
        
    
                
                                    A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                05/07/2025
            
            Locations: Clinical Research Solutions LLC, Cypress, Texas  +5 locations         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    Invasive Brain-Computer Interfaces for Attention
                                
            
            
        Recruiting
                            
            
                The goal of this interventional study is to compare if the use of a brain-machine interface (BCI) therapy can improve the symptoms of attentional deficit by producing brain changes in the networks that modulate attention. The investigators intend to work with epileptic participants who do not respond to pharmacological treatment, who will undergo neurosurgery. The questions the study sets out to answer are:
1. is there an improvement of symptoms in an experimental group receiving the treatment...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 8 years and 21 years
            Trial Updated:
                04/18/2025
            
            Locations: Dell Children's Medical Center, Austin, Texas         
        
        
            Conditions: Epilepsy in Children, Epilepsy
        
            
        
    
                
                                    FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
                                
            
            
        Recruiting
                            
            
                This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                04/03/2025
            
            Locations: UTHealth Houston, Houston, Texas         
        
        
            Conditions: Mesial Temporal Lobe Epilepsy
        
            
        
    1 - 12 of 28
            